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Abstract
Objective: To compare the responsiveness of six common patient-reported outcomes (PROs) following autologous 
chondrocyte implantation (ACI). Design: A systematic search was conducted to identify reports of PROs following ACI. 
Study quality was evaluated using the modified Coleman Methodology Score (mCMS). For each outcome score, pre- to 
postoperative paired Hedge’s g effect sizes were calculated with 95% confidence intervals (CIs). Random effects meta- 
analyses were performed to provide a summary response for each PRO at time points (TP) I (1 year), II (1 year to
2 years), III (2 years to 4 years), IV (4 years), and overall. Results: The mean mCMS for the 42 articles included was 50.9 
9.2. For all evaluated instruments, none of the mean effect size CIs encompassed zero. The International Knee 
Documentation Committee Subjective Knee Form (IKDC) had increasing responsiveness over time with TP-IV, 
demonstrating greater mean effect size [confidence interval] (1.78 [1.33, 2.24]) than TP-I (0.88 [0.69, 1.07]). The Knee 
Injury and Osteoarthritis Outcome Score–Sports and recreation subscale (KOOS-Sports) was more responsive at TP-III 
(1.76 [0.87, 2.64]) and TP-IV (0.98 [0.81, 1.15]) than TP-I (0.61 [0.44, 0.78]). Overall, the Medical Outcomes Study 36-Item 
Short Form Health Survey Physical Component Scale (0.60 [0.46, 0.74]) was least responsive. Both the Lysholm Scale (1.42 
[1.14, 1.72]) and the IKDC (1.37 [1.13, 1.62]) appear more responsive than the KOOS-Sports (0.90 [0.73, 1.07]). All other 
KOOS subscales had overall effect sizes ranging from 0.90 (0.74, 1.22) (Symptoms) to 1.15 (0.76, 1.54) (Quality of Life). 
Conclusions: All instruments were responsive to improvements in function following ACI. The Lysholm and IKDC were 
the most responsive instruments across time. IKDC and KOOS-Sports may be more responsive to long-term outcomes, 
especially among active individuals.
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Introduction
The limited ability of articular cartilage to heal on its own 
has been a topic of discussion for more than 200 years.1 The 
treatment and management of articular cartilage damage 
can be particularly challenging in the knee joint where 
such defects are frequently observed during arthroscopy.2-5 
Restorative and reparative treatment of these defects is 
highly desirable to prevent the progression of osteoarthri-
tis.6 Over the last three decades, approaches to treating 
chondral defects have shifted toward cell-based therapies. 
One of the most frequently used and well studied is the 
autologous chondrocyte implantation (ACI).7
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Treatment Evaluation
As new methods for treating cartilage are developed, it is 
necessary to evaluate these treatments to determine their 
effectiveness. Although second look arthroscopies with 
cartilage biopsies may provide the most diagnostic method 
of evaluating cartilage repair, they are not always feasible 
or ethical to perform. Furthermore, biopsies allow for the 
assessment of the histological tissue repair but cannot 
be used to evaluate patient-oriented outcomes such as pain 
and function. To evaluate patient-oriented outcomes, inves-
tigators have relied on patient-reported outcome (PRO) 
instruments. Many PROs have been developed to address 
outcomes associated with a specific body part or region, a 
specific disease, or health-related quality of life as a whole. 
Numerous PROs have been used to document patient 
response to cartilage repair. Although the widespread use 
of PROs is beneficial for documenting treatment outcomes, 
the wide variety in PROs makes comparison across studies 
and instruments difficult. Ideally, a standard instrument or 
battery of instruments would be advantageous for reliable 
and valid assessment of patient response to treatment.
Some of the most commonly used PROs to evaluate 
articular cartilage repair outcomes include the Medical 
Outcomes Study 36-Item Short Form Health Survey 
(SF-36),8-10 the International Knee Documentation Committee 
Subjective Knee Form (IKDC),11 the Lysholm Knee Scale 
(Lysholm),12,13 the Modified Cincinnati Knee Rating 
System (MCKRS),14 the Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC),15,16 and the 
Knee Injury and Osteoarthritis Outcome Score (KOOS).17 
Test–retest reliability and validity among cartilage patients 
has previously been established for a version of each of 
these instruments.18-21 Although all these instruments have 
been widely used to evaluate ACI treatment efficacy, there 
is no clear standard regarding which outcome instrument is 
ideal for evaluating treatment effects following ACI.
PRO responsiveness is the evaluation of change in the 
instrument score over time in response to treatment.18 The 
reported responsiveness in self-reported function following 
ACI has not been compared among instruments. Identification 
of the most responsive instrument for an ACI population will 
provide clinicians and researchers with a specific PRO instru-
ment to compare treatment effects between therapies.
The purpose of this study was to systematically review 
and summarize the scientific literature evaluating changes 
in PRO scores after ACI. For analysis, we selected com-
monly used outcome instruments in cartilage repair studies, 
including the IKDC, Lysholm, MCKRS, KOOS, WOMAC, 
and SF-36. The outcome of interest was PRO responsive-
ness following ACI treatment. Meta-analyses of PRO score 
changes (“Hedge’s g effect sizes with 95% CIs) were plot-
ted among instruments to visually reflect the responsive-
ness of each instrument at specified postoperative time 
points (TPs) forest plots of mean effect sizes for each 
instrument at each TP were used to provide a graphical rep-
resentation of how responsive each instruments is to 
changes in self-reported knee function at varying postoper-
ative TPs. A better understanding of the responsiveness of 
each instrument will allow for improved selection of out-
come instruments in future cartilage research.
Methods
This nonregistered review was prepared in accordance with 
the “The PRISMA Statement for Reporting Systematic 
Reviews and Meta-Analyses of Studies that Evaluate Health 
Care Interventions.”22
Evidence Acquisition
Search strategy. In February 2011, investigators conducted 
a systematic search of the literature using CINAHL (from 
1981), Medline (from 1966), and SPORTDiscus (from 
1800) to identify reports of PROs following autologous 
chondrocyte implantation/transplantation. Search terms 
used were autologous, chondrocyte, outcome, and knee. All 
abstracts were then reviewed for study inclusion/exclusion. 
In the event the abstract did not provide sufficient informa-
tion to determine study eligibility, the full manuscript was 
reviewed. Additionally, the reference lists of all included 
studies were reviewed to identify other potentially eligible 
studies.
Selection criteria. All studies were required to meet the 
following inclusion criteria: (a) publication in English; 
(b) investigations with human participants; (c) prospective 
evaluation of patient outcomes following cell-based treat-
ment of articular cartilage defects with some form of cul-
tured autologous chondrocytes; (d) utilization of at least 
one of the following PRO instruments: IKDC, Lysholm, 
MCKRS as described by Browne et al.,14 KOOS, WOMAC, 
or SF-36 Physical Component Scale (SF-36 PCS) preopera-
tively and at a minimum of one postoperative TP; and 
(e) reporting of statistics from which effect sizes and 95% 
confidence intervals (CIs) could be calculated.
Assessment of Methodological 
Quality and Level of Evidence
The quality of all studies included was assessed using the 
Coleman Methodology Score modified by Kon, Verdonk, 
and others.23,24 This assessment tool was specifically 
adapted to evaluate the quality of cartilage repair studies 
and includes 11 parameters on a 100-point scale (100 = 
highest quality): study sample size (10 points), average 
follow-up (10), number of concomitant surgical procedures 
(10), study design (15), description of the surgical proce-
dure (5), description of postoperative rehabilitation (5), the 
inclusion of MRI outcome (10), the inclusion of histologi-
cal outcome (10), outcome criteria (5), procedure for 
assessing clinical outcomes (7), and description of subject 
selection process (8).24
Level of evidence was evaluated based on criteria from 
the Centre for Evidence Based Medicine (CEBM).25 Using 
this taxonomy, the quality of the evidence for the studies 
included was determined and a grade of recommendation 
was generated for the use of each PRO as a measure of ACI 
treatment effect.25 Methodological quality assessment and 
the rating of the level of evidence were assessed indepen-
dently by two investigators. Discrepancies in scoring were 
discussed until a consensus score was agreed upon.
Data Extraction
The primary outcome variables of interest were scores on 
six specified PROs: the IKDC, Lysholm, MCKRS, KOOS, 
WOMAC, and SF-36 PCS. Because of the variation in 
Modified Cincinnati Knee Rating Systems reported in the 
literature, only the MCKRS presented by Browne et al.14 
was reviewed. To avoid inappropriate comparisons of vari-
ous versions of the MCKRS, the studies included had to 
have either published the scale in the article or provided a 
clear reference. From each study all data that could be used 
to calculate effect sizes for PROs were extracted.
For each outcome score, individual pre to postoperative 
standardized effect sizes were calculated using bias-corrected 
Hedge’s g for paired samples26 with 95% confidence inter-
vals (CIs) to examine the magnitude and precision of the 
difference between pre- and postoperative PRO scores. 
These effect sizes are unitless measures, corrected to repre-
sent a parametric distribution of the effects. For the purpose 
of this study, Hedge’s g effect sizes were used as a measure 
of responsiveness with larger effect sizes representing 
increased responsiveness of an instrument—that is, greater 
change in the instrument score over time.18 Separate meta-
analyses were performed to provide a summary response 
for each PRO at specified TPs. For the purposes of analysis, 
follow-up TPs were grouped into four categories, TP-I 
(<1 year), TP-II (1 year to <2 years), TP-III (2 years to 
<4 years), and TP-IV (4 years or more). Most studies made 
multiple comparisons across separate TPs, and each com-
parison was treated independently during statistical analy-
ses. If a study reported multiple results within a given TP 
category (e.g., 3 months and 6 months are both within the 
<1 year TP category), only the latest data point (i.e., 6 months) 
was analyzed. Therefore, within each study, only a single 
result per instrument was included for a given TP category. 
For each PRO, an additional meta-analysis to determine the 
overall responsiveness across all TPs was conducted using 
the pooled standardized effects averaged across all available 
TPs. For each meta-analysis, a random effects model was 
employed.26
Effect sizes, 95% CIs, and Z-distribution P values were 
calculated in Comprehensive Meta Analysis (Comprehensive 
Meta Analysis Version 2.0, Biostat, Englewood, NJ). A 
positive effect size indicated improvement in postoperative 
PRO score compared with preoperative score. Effect sizes 
for which CIs did not overlap were considered to be sub-
stantially different. Effect size values were interpreted as 
small if they were between 0.20 and 0.49, moderate if 
between 0.50 and 0.79, and large if more than 0.80.
Assessment of Bias
Methodological bias was assessed using part B of the 
modified Coleman Methodology Score.24 To assess the 
likelihood of publication bias, a funnel plot of all measures 
was generated by plotting standard error against Hedge’s g 
effect size for each included study. To assess the robust-
ness of the observed overall effects of the variations in 
study design on PRO score, Orwin’s Fail-Safe N test was 
employed.27 For this test, a Hedge’s g effect size of 0.1 was 
assumed for all missing studies, or studies excluded due to 
publication bias, and the number of missing studies neces-
sary to reduce the overall mean effect size for each instru-
ment to a 0.4 was calculated.
Results
Study Selection
The initial literature search yielded 216 results. Application 
of inclusion and exclusion criteria resulted in the inclusion 
of 42 articles.14,28-68 Study selection and inclusion is 
depicted in fig 1. The included studies are summarized in 
Table 1. A total of 2,016 patients with a mean age of 
approximately 34.5 years are reported on across all studies. 
Overall, 16 studies reported outcomes using the IKDC, 11 
used the KOOS (2 reporting only total KOOS scores), 18 
used the Lysholm, 12 used the MCKRS, 9 studies used the 
SF-36 PCS, and 2 studies used the WOMAC. A single 
study reported on four instruments.58 All other studies 
reported on three or fewer instruments.
Methodology Scoring and Level of Evidence
The mean modified Coleman Methodology Score for all 
included articles was 50.9 ± 9.2 (range = 35-68). The 
mean modified Coleman Methodology Score for studies 
using each PRO instrument was as follows: IKDC 51.4 
(standard deviation [SD] = 7.5), KOOS-Sports 51.9 (5.8), 
KOOS-all other subscales 53.7 (7.7), Lysholm 49.2 (8.8), 
MCKRS 48.2 (8.8), and SF-36 PCS 56.2 (7.8). The least 
reported parameters were inclusion of MRI and histologi-
cal outcomes and description of the subject selection 
process. CEBM level of evidence was 2b for 38 articles 
and 1b for 4 articles included. Based on the consistent 
reporting of level 2 studies, a grade B recommendation 
was made for the use of the IKDC, KOOS, Lysholm, 
MCKRS, SF-36 PCS, and WOMAC as outcome measures 
following ACI.25
Assessment of Bias
The mean score for Part B of the modified Coleman 
Methodology Score assessing individual study bias was 
13 ± 3 out of a possible 22 points. The assessment of pub-
lication bias revealed an asymmetrical distribution of stud-
ies with a disproportionate number of studies above the 
mean effect size at the bottom of the funnel (Fig. 2). This 
indicated a slight publication bias toward studies demon-
strating large treatment effects, particularly for studies 
with smaller sample sizes. However, the results of Orwin’s 
Fail Safe N test (Table 2) demonstrate that an additional 
14 (SF-36 PCS) to 196 (KOOS) studies with a trivial effect 
size of 0.10 are necessary to reduce the mean effect size 
for any of the PROs to a weak value of 0.40. Therefore, 
the observed overall effects are very robust and not likely 
to be artificially influenced by this potential publication 
bias.
Responsiveness of PROs
Mean effect sizes and 95% CIs for each instrument at each 
of the four TPs are reported in the forest plots in fig 3. For 
an instrument to be included in the meta-analysis at a given 
TP, a minimum of four individual data points must have 
been reported. The WOMAC did not meet this require-
ment at any time point, and the SF-36 PCS only met this 
requirement at TP-III. The MCKRS could only be evalu-
ated at TP-III and TP-IV and only the patient perception 
scale could be evaluated.
Responsiveness by Instruments across TPs
For all evaluated instruments, none of the mean effect sizes 
or CIs encompassed zero. This indicated that there was 
evidence of positive treatment effects following ACI 
regardless of the PRO used (Fig. 3). The IKDC increased 
responsiveness over time, with TP-IV demonstrating a 
greater mean effect size (mean effect size [95% CI]: 1.78 
[1.33, 2.24]) than TP-I (0.88 [0.69, 1.07]). The responsive-
ness of the Lysholm varied little across TPs, with mean 
effect sizes only ranging from 1.29 to 1.69. There was also 
no difference in responsiveness for the MCKRS between 
TP-II and TP-III. Finally, the only KOOS subscale to show 
noticeable improvements in responsiveness over time was 
the KOOS-sports and recreation subscale (KOOS-Sports) 
for which TP-III (1.76 [0.87, 2.64]) and TP-IV (0.98 [0.81, 
1.15]) demonstrated larger effect sizes than TP-I (0.61 
[0.44, 0.78]). Effect sizes for the remaining KOOS sub-
scales did not change over time and fell in the following 
ranges: KOOS-Activities of Daily Living 0.78 [0.27, 1.29] 
to 1.90 [1.02, 2.78], KOOS-Pain subscale 0.75 [0.40, 1.10] 
to 1.88 [1.12, 2.63], KOOS-Quality of Life 0.88 [0.32, 
1.44] to 2.38 [1.20, 3.56], and KOOS-Symptoms 0.75 
[0.50, 1.00] to 1.60 [0.79, 2.41].
Responsiveness by TP
At TP-I, the Lysholm (1.52 [0.92, 2.11]) appears more 
responsive than the KOOS-Sports subscale (0.61 [0.44, 
0.78]). At TP-II, both the IKDC (1.37 [0.93, 1.80]) and the 
Lysholm (1.53 [0.96, 2.11]) were more responsive than the 
KOOS-Sports subscale (0.57 [0.23, 0.92]). There were no 
identifiable differences between any of the instruments at 
TP-III. Finally, at TP-IV the IKDC (1.78, [1.33, 2.24]) 
demonstrated a larger effect size than the KOOS-Sports 
subscale (0.98 [0.81, 1.15]).
Overall Responsiveness
The final comparison was of the overall responsiveness of 
each instrument with data from all available TPs averaged 
(Fig. 4). Both the Lysholm (1.43 [1.14, 1.72]) and the 
IKDC (1.37 [1.13, 1.62]) had overall mean effect sizes that 
Figure 1. Study selection results.
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Effect Size
IKDC
Lysholm
MCKRS
SF-36 PCS
KOOS-ADL
KOOS-Pain
KOOS-QOL
KOOS-Sports
KOOS-Symptoms
Time I41, 45, 54, 55
Time II33, 39, 41, 45, 47, 52, 54, 55, 65, 68
Time III37-41, 45, 47, 52, 55, 57, 60, 62, 64, 67, 68
Time IV33, 37, 44, 45, 48, 58
Time I28, 42, 55, 66
Time II28, 30, 42, 43, 52, 55, 66, 68
Time III28, 29, 31, 42, 43, 52, 54, 56, 62, 66, 68
Time IV36, 48, 51, 58, 59
Time III40, 41, 52, 61, 67
Time IV14, 36, 46, 49, 50, 53, 67
Time III40, 41, 43, 61
Time I34, 45, 57, 60, 64
Time II45, 57, 60, 64, 67
Time III57, 60, 62, 67
Time IV45, 48, 58, 67
Time I34, 45, 57, 60, 64
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Figure 3. Effect sizes by patient-reported outcome instrument. 
Random effects model summary mean effect sizes for each patient-
reported outcome instrument by time point. IKDC = International 
Knee Documentation Committee Subjective Knee Form; Lysholm = 
Lysholm Knee Scale; KOOS-ADL = Knee Injury and Osteoar-
thritis Outcome Score Activities of Daily Living subscale; KOOS-
pain = Knee Injury and Osteoarthritis Outcome Score Pain sub-
scale; KOOS-QOL = Knee Injury and Osteoarthritis Outcome 
Score Quality of Life subscale; KOOS-Sports = Knee Injury and 
Osteoarthritis Outcome Score Sports and Recreation subscale; 
KOOS-Symptoms = Knee Injury and Osteoarthritis Outcome 
Score Symptom subscale; MCKRS Patient = Modified Cincinnati 
Knee Rating System Patient Perspective; SF-36 PCS = Medical 
Outcomes Study 36-Item Short Form Health Survey Physical 
Component Scale; WOMAC = Western Ontario and McMaster 
Universities Osteoarthritis Index. 
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Figure 2. Funnel plot to evaluate publication bias. The observed 
funnel plot suggests a slight publication bias toward studies 
demonstrating larger effect sizes, with an asymmetrical distribution 
of studies at the bottom of the funnel.
were greater than the overall mean effect size for the 
KOOS-Sports subscale (0.90 [0.73, 1.07]) and SF-36 PCS 
(0.78 [0.52, 1.05]). CIs for all other instruments and all 
other KOOS subscales can be observed to overlap, suggest-
ing no differences in responsiveness.
Discussion
Our purpose was to evaluate the responsiveness of common 
PROs to the treatment effects of ACI. An underlying 
assumption was that ACI would have a common effect 
across studies and varying ACI procedures. Evaluating ACI 
efficacy was not a purpose of this review, and the results 
are in agreement with previous reviews documenting ACI 
to be a viable procedure resulting in positive patient out-
comes.24,69,70 The large mean effect sizes and narrow CIs 
observed in this review support the use of ACI for the gen-
eralized treatment of articular cartilage defects.
Responsiveness
The results of this review demonstrate that regardless of 
the duration of postoperative follow-up all instruments 
Table 2. Orwin’s Fail Safe N Analysis to Evaluate Publication 
Bias
Instrument Na
IKDC 95
Lysholm 83
KOOS 196
MCKRS 48
SF-36 PCS 14
Overall across all instruments 399
IKDC = International Knee Documentation Committee Subjective 
Knee Form; Lysholm = Lysholm Knee Scale; KOOS = Knee Injury and 
Osteoarthritis Outcome Score; MCKRS = Modified Cincinnati Knee 
Rating System; SF-36 PCS = Medical Outcomes Study 36-Item Short 
Form Health Survey Physical Component Scale.
aNumber of studies with an effect size of 0.1 needed to reduce the 
overall mean effect size to 0.4.
were responsive to patient improvement; however, the IKDC 
and Lysholm may be more responsive than the MCKRS, 
KOOS, or SF-36 PCS. There was insufficient data to ade-
quately evaluate the WOMAC.
Responsiveness of PROs across TPs
The Lysholm demonstrated large mean effect sizes (1.30-
1.70) with little variation across time (Fig. 2). The observed 
CIs for the Lysholm at all TPs overlap by more than 50%, 
suggesting little changes in responsiveness as time since 
ACI progresses. Common rehabilitation recommendations 
following ACI restrict return to sports participation for 12 
to 18 months following surgery.71-73 This delayed return to 
physical activity may result in lower scores on instruments 
that emphasize higher sport demands. Because the Lysholm 
primarily assesses everyday activities (walking, squatting, 
stair-climbing) and does not address sports activity, delayed 
return to higher level physical activity has little influence 
on Lysholm score. Therefore, the Lysholm scale may be 
ideal for evaluating short-term outcomes or outcomes 
among patients not intending to return to sports, but less 
responsive to changes during long-term recovery as indi-
viduals return to higher demand activities. Additionally, it 
should be noted that some authors and investigations 
have called into question the current weighting system for 
Lysholm items.74,75
The IKDC also demonstrated large effect sizes. With a 
noticeable increase in mean effect size observed between 
TP-I and TP-IV, with mean effect size increasing from 0.88 
to 1.78 with no overlap between CIs. This difference dem-
onstrates increased treatment effects over time when evalu-
ating outcomes with the IKDC. Greco et al.20 observed a 
similar trend with responsiveness of the IKDC increasing 
between 6 and 12 months in a cohort of surgical cartilage 
patients. It has previously been reported76-78 that functional 
and structural improvements following cartilage repair con-
tinue beyond 1 year postoperatively. The observed increases 
in mean effect size over time may represent the IKDC’s 
responsiveness to continual improvements in function that 
occur in the years following ACI. The responsiveness of the 
IKDC to continued improvements over time can be consid-
ered a strength of this instrument and may be due to its 
inclusion of sporting activities. The IKDC allows for con-
tinued improvement as individuals initiate return to strenu-
ous activity and sports participation beyond 1 year 
postoperatively.
The KOOS-Sports subscale had the lowest mean effect 
at TP-I and TP-II, whereas the KOOS-Symptoms subscale 
had the lowest mean effect of all the KOOS scales at TP-III 
and TP-IV. Effect sizes for the KOOS-Sports subscale were 
lower at TP-I compared with TP-III and TP-IV. These 
results are similar to those observed with the IKDC, and this 
progressive increase in effect sizes over time may be related 
to the slow, progressive return to sports following ACI. For 
all other KOOS subscales no changes were seen for mean 
effect size between TPs. Overall, the KOOS was responsive 
to changes following ACI; however, the KOOS-Sports sub-
scale was the only subscale to demonstrate increasing 
responsiveness over time, suggesting that it responded to 
increasing treatment effects as healing progressed and may 
be more sensitive to improvements in function among active 
individuals than other instruments or KOOS subscales.
There were only sufficient data to evaluate the MCKRS 
at TP-III and TP-IV, limiting any conclusions that can be 
drawn regarding the changes in its effect sizes over time. 
Our results suggest the MCKRS is responsive to changes in 
patient function following ACI; however, caution is urged 
regarding the use of this instrument. Many different ver-
sions of the MCKRS exist and many authors fail to refer-
ence the version of MCKRS they use. Several articles were 
excluded, at least in part, because the authors did not refer-
ence the version of the MCKRS used, or because a different 
version than the one presented by Browne et al.14 was used 
as an outcome measure.76,79-87 Because of ambiguity regard-
ing the use of “modified” Cincinnati Knee Rating Systems, 
the developers of the original Cincinnati Knee Rating Scale 
discourage the use of any modified versions.88 However, 
-1 0 1 2
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Figure 4. Overall effects sizes for each patient-reported 
outcome. Random effects model summary mean effect sizes 
for each patient-reported outcome instrument across all time 
points combined. IKDC = International Knee Documentation 
Committee Subjective Knee Form; Lysholm = Lysholm Knee Scale; 
KOOS-ADL = Knee Injury and Osteoarthritis Outcome Score 
Activities of Daily Living subscale; KOOS-Pain = Knee Injury and 
Osteoarthritis Outcome Score Pain subscale; KOOS-QOL = Knee 
Injury and Osteoarthritis Outcome Score Quality of Life subscale; 
KOOS-Sports = Knee Injury and Osteoarthritis Outcome Score 
Sports and Recreation subscale; KOOS-Symptoms = Knee Injury 
and Osteoarthritis Outcome Score Symptom subscale; MCKRS 
Patient = Modified Cincinnati Knee Rating System Patient 
Perspective; SF-36 PCS = Medical Outcomes Study 36-Item Short 
Form Health Survey Physical Component Scale; WOMAC = Western 
Ontario and McMaster Universities Osteoarthritis Index.
because of the frequency with which the Browne et al.14 
version of the MCKRS has been clearly referenced in ACI 
outcomes studies, it was chosen for inclusion in this review.
Both the SF-36 PCS and the WOMAC had limited data 
available for analysis. For the SF-36 PCS, there was only 
sufficient data for analysis of responsiveness at TP-III. For 
this TP, the SF-36 PCS did demonstrate a positive mean 
effect 2 to 4 years following ACI with an effects size of 0.92 
[0.55, 1.28]. There were insufficient data to include the 
WOMAC in any of the meta-analyses performed.50,61 
Although additional studies have included the WOMAC as 
an outcome measure, the results were only reported using 
nonparametric statistics and/or without the reporting of 
means and standard deviations or other data necessary for 
calculating effect sizes.89-92 As a result no clear conclusions 
regarding the responsiveness of the WOMAC as an out-
come instrument can be reached based on this review.
Responsiveness between PROs
The forest plots of PRO instruments for each TP can be 
seen in fig 3, whereas the overall mean effect sizes aver-
aged across all TPs can be seen in fig 4. The IKDC and the 
KOOS-Sports were the only instruments to demonstrate 
changes in effect sizes over time. These changes may be 
related to activity restriction and gradual return to sports 
following ACI. The restrictions on sporting activity during 
the first year post-ACI may also explain the significant dif-
ferences observed between the responsiveness of the 
KOOS-Sports and the Lysholm at TP-I and TP-II. At TP-II 
and TP-IV, the IKDC appears more responsive than the 
KOOS-Sports. These differences may be the result of the 
wider range of physical functioning addressed in the IKDC 
as compared with the KOOS-Sports. The responsiveness of 
the MCKRS was not different from any other instrument 
evaluated at both TP-III and TP-IV. The SF-36 PCS had the 
lowest responsiveness overall and at TP-III. This finding is 
not surprising as the SF-36 was the only included instru-
ment not specifically designed for the knee.
The Lysholm and the IKDC demonstrated the largest 
overall effect sizes, regardless of TP. These had appreciably 
greater responsiveness than the KOOS-Sports subscale and 
the SF-36 PCS (Fig. 4). Should investigators or clinicians 
wish to explore patient outcomes for individual constructs 
(quality of life, activities of daily living, sports, etc.), the 
KOOS via its subscales is the only instrument that allows 
for this multifaceted investigation, and along with the IKDC 
has been recommended for use by the International Cartilage 
Repair Society.75 Although both the KOOS and IKDC 
include sports participation as components of evaluating 
knee function, the IKDC appears more responsive to overall 
changes in function following ACI (Fig. 4). This overall 
difference, combined with the observed differences in 
responsiveness between the IKDC and KOOS-Sports 
subscales at TP-II and TP-IV, leads us to propose that the 
IKDC may be the preferred outcome instrument for evaluat-
ing long-term outcomes following ACI, particularly among 
patients whose goals include return to sporting activity. 
Although all KOOS subscales are responsive to treatment 
effects following ACI, the IKDC and Lysholm are shorter 
instruments with single score outcomes and overall are 
more responsive to change than some subscales included in 
the KOOS. Based on these observations, the IKDC and the 
Lysholm may be preferable to the KOOS for documenting 
treatment effects following ACI.
Study Quality
The mean modified Coleman Methodology Score (50.9 ± 
9.2) among studies was comparable to other recent reviews 
of ACI and other cartilage repair procedures.44,69,93 Although 
the modified Coleman Methodology Score provides a set of 
standardized criteria by which to evaluate cartilage research, 
it is not without limitations. The scale is heavily weighted 
toward diagnostic, clinician-oriented outcomes, with up to 
25% of the score dependent on MRI and histological evalu-
ation. The relationship between MRI and clinical outcomes 
is not definitive; some authors observed low to moderate 
correlations between MRIs and PROs,60,94,95 and others 
failed to observe such a relationship.96,97 Similarly, histo-
logical analysis can involve a wide variety of techniques 
and may not be ethical in cases where reoperation is not 
otherwise indicated. Of the 42 studies included, only a 
single study65 received full credit for both histological and 
MRI outcomes, suggesting that the requirement of these 
outcomes may not be applicable in a clinical research set-
ting. Furthermore, only five studies scored a full 10 points 
for >90% of subjects undergoing one surgical procedure 
with <10% undergoing concomitant procedures.29,42,43,62,65 
Notably, although concomitant procedures reduced the 
overall methodological score, studies that include con-
comitant procedures are more generalizable to real clinical 
practice than studies of single isolated defects.98
In future research, more well-designed, well-documented, 
high-level clinical trials that use PROs with comprehensive 
data reporting are needed. Adopting uniform methodologi-
cal reporting requirements for cartilage repair studies will 
improve the quality of the body of literature in this area. 
This review may provide a basis for this effort.
Limitations
The results of this review are limited by the quantity, 
quality, and strength of the studies and PROs selected for 
inclusion. Any recommendations made are based solely 
on the available evidence, and it should be noted that the 
IKDC and Lysholm were used in the literature more often 
than other instruments, strengthening the validity of 
recommendations regarding these two instruments and 
limiting our ability to draw conclusions regarding other 
PROs. As evidenced by the low modified Coleman 
Methodology Score observed in this review and others, 
the quality of reporting in cartilage outcomes studies is 
variable and generally poor. A random effects analysis 
was used to account for the variability between studies 
allowing our results to be generalized to a broad clinical 
population.
A statistical limitation of our study is the use of multiple 
measures at multiple TPs from within the same study popu-
lations. We acknowledge that outcome scores obtained 
from within the same sample are likely correlated, but given 
that the correlation between outcome measures and TPs is 
rarely reported and no studies documented all instruments 
at all TPs, correction for this relationship was not feasible. 
Fortunately, the observed mean effect sizes are so large and 
the CIs so small for the included outcome instruments that 
we do not believe this assumption violation significantly 
influences the overall conclusions of this review.
Conclusions
Evidence for the use of ACI as a treatment for chondral 
defects consists primarily of level 2b observational cohort 
studies. The methodological quality of many of these stud-
ies is limited by the absence of diagnostic outcomes such as 
MRI and histological analyses, small sample size, short 
follow-up, and high frequency of concomitant procedures. 
In addition, documentation of recruitment rate and investi-
gator independence was lacking from many studies. The 
IKDC, Lysholm, KOOS, MCKRS, and SF-36 PCS were all 
responsive to improvements in function following ACI. A 
positive treatment effect for ACI was observed using all 
instruments with follow-up ranging from <1 year to beyond 
4 years. The Lysholm and the IKDC were the most respon-
sive instruments across time. The Lysholm was highly 
responsive as early as <1 year following ACI and was con-
sistently responsive throughout follow-up. However, this 
instrument may not be responsive to changes in function 
associated with the resumption of higher demand activities 
such as sports that occurs after 1 year. For the evaluation of 
long-term outcomes among patients with intent to return to 
physical activity, this review supports the use of the IKDC, 
which was able to detect increasing treatment effects over-
time. The use of the Lysholm and IKDC together represents 
a responsive combination of PRO instruments that are able 
to efficiently document both short-term and long-term 
treatment effects among patients of a variety of activity 
levels following ACI.
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